Tuesday, 20 February 2018

Care Management Solutions Market Analysis, Drivers, Growth Rate, Specifications and Forecast to 2023


The growth of global care management solutions market is led by growing geriatric population, increasing demand for quality of care and increasing government initiatives to promote patient-centric care, increasing prevalence of chronic diseases, advancing IT and big data capabilities and growing medical tourism. Initiatives to move the burden of threat from healthcare payers to providers and need to reduce healthcare cost are further expected to boost the demand of these solutions. The fastest increase in demand of care management solutions during the forecast period is expected to be witnessed in chronic care management segment, due to increasing demand of improving quality of care and save time for providers. Based on component, software segment leads the global market in terms of size, due to technological advancement in IT solution, growth of cloud computing and increased access of internet across the globe.


Increasing prevalence of chronic diseases is driving the growth of the global care management solutions market due to increasing demand for quality of care. The prevalence of chronic diseases, such as heart disease, cancer, stroke and respiratory disease, are increasing due to the alteration in lifestyle and lack of access to preventive care. According to the Centers for Disease Control and Prevention (CDC), approximately 117 million people in the U.S. had one or more chronic health conditions in 2012.

Care management solution is an integrated healthcare solution that offers products and services to improve quality of care of patients. It identifies the need of care, manage care, monitor results and outcomes, assess patient’s needs, and establish the appropriate care plan to support their needs. It combines analytics, data integration, and coordination of care capabilities into a single solution.


The key players operating in the global market are Allscripts Healthcare solutions Inc., Cerner Corporation, Epic Corporation, Inc., Wellentive Inc., I2I System Inc, and IBM Corporation.

Monday, 19 February 2018

Infection Surveillance Solutions Market - Global Industry Insights, Size, Share and Growth till 2023

Infection is the invasion and multiplication of microorganisms such as viruses, bacteria and parasites that are not normally present within the human body. An infection may cause no symptoms and be hidden, or it may cause symptoms and be clinically visible. An infection may remain localized, or it may spread through the blood or lymphatic vessels to become systemic (present in the entire body). The global infection surveillance solutions market is growing due to the emergence of diseases caused by microorganisms that were previously not known. The microorganisms living naturally within the body are not considered as infectious for example, bacteria that normally live within the mouth and intestine such as E. coli do not cause an infection to the body. Hospital associated infections such as urinary tract infection, surgical site infections and pneumonia are increasing due to the use of contaminated devices, patient clothing, and other materials used in hospitals and clinics. This has thus provoked healthcare professionals and hospitals to adopt infection surveillance solutions to identify possible infections during the time the patient remains in hospital, and to develop necessary preventive measures for the same. These infection surveillance solutions also aid in diagnosing antibiotic resistant organisms (AROs) and infections due to non-sterile medical devices.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/infection-surveillance-solutions-market/report-sample

Geographically, North America accounts for the largest market share in the global infection surveillance solutions market, which is attributable to the increasing occurrence of HAIs, favorable government policies for preventing HAIs, and rising healthcare expenditure in this region. Asia-Pacific region is expected to record the highest growth in the global market on account of rising incidences of HAIs, increased awareness and accessibility to advanced healthcare facilities, rising healthcare spending, and rapid improvement in the health insurance sector in this region.

Various players in the infection surveillance solutions market are focusing on collaborating with other companies to expand their product and service offerings as well as introduction of new treatment methods into the infection surveillance solutions market.
In June, 2017, BD MAX, a newly developed molecular test of Becton, Dickinson and Company, received 510(k) clearances from the U.S. Food and Drug Administration (FDA) for detecting intestinal bacteria that causes infectious diarrhea. The BD MAX was aimed at detecting majority of pathogens that cause acute gastroenteritis, ultimately leading to hospitalization.
In June, 2017, Wolters Kluwer announced that Point of Care (POC) Advisor, its real-time clinical surveillance and analytics platform, was to integrate the Natural Language Processing (NLP) solution from Hiteks Solutions, Inc. for inclusion of unstructured and structured documentation to make them immediately come into action. The purpose of the integration was to enable real-time analysis of physician notes for infection sources, presence of one or more diseases occurring at the same time and other clues to the presence of sepsis.
Some of the other key players in global market are, Premier Inc., Baxter International Inc., Gojo Industries, Inc., Truven Health Analytics (An IBM Company), DEB Group Ltd., Hygreen, Inc., Atlas Medical Software, and RL Solutions.

Friday, 16 February 2018

Acromegaly Therapeutics Pipeline Review 2018

Acromegaly is a type of hormonal disorder that causes excessive release of growth hormone from pituitary gland in the body. Acromegaly is generally diagnosed in middle aged adults. Some of the complications associated with acromegaly are increased risk of cardiovascular disease, high blood pressure, arthritis, type 2 diabetes, and colon polyps. One of the common symptoms of acromegaly is abnormal growth of hands and feet. In addition, release of excess growth hormone is observed in noncancerous tumours of pituitary gland which is called adenomas. Amryt Pharma plc is in the process of developing AP102 as a growth factor receptor antagonist for the treatment of acromegaly. Strongbridge Biopharma plc is in the process of developing veldoreotide as a somatostatin analogue for the treatment of acromegaly. Some of the companies having the pipeline of acromegaly include Midatech Pharma Plc, Strongbridge Biopharma plc, and others.


The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Explore Report sample at: https://www.psmarketresearch.com/market-analysis/acromegaly-therapeutics-pipeline-analysis/report-sample

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Web: https://www.psmarketresearch.com

Thursday, 15 February 2018

Neisseria Gonorrhoeae Infections Therapeutics - Pipeline Review 2018

Neisseria gonorrhoeae infections is a sexually transmitted disease that is caused by Neisseria gonorrhoeae bacterium which cause infections in throat, rectum, and genitals. In men, the observed symptoms of gonorrhoeae infections are burning sensation during urination, painful and swollen testicles, and white, green or yellow discharge from the penis. In women, the observed symptoms of gonorrhoeae are vaginal bleeding during periods, increased vaginal discharged, and burning sensation during urination. The unprotected vaginal, oral or anal sex are the risk factors for gonorrhoeae infections. Entasis Therapeutics, Inc. is in the process of developing ETX0914 as a bacterial type II topoisomerases inhibitor, for the treatment of gonorrhoeae infections. Therapyx, Inc. is also in the process of developing IL12 NanoCap for the treatment of gonorrhoeae infection. Some of the companies having the pipeline of neisseria gonorrhoeae infections include Therapyx, Inc., Entasis Therapeutics, Inc., and others.


The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.


About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Web: https://www.psmarketresearch.com

Melasma Therapeutics Clinical Trials Review 2018

Melasma, also known as chlosma, is characterized by localized, chronic acquired hypermelanosis of the skin that occur due to melanogenesis dysfunction. It is characterized by the appearances of brown macules distributed symmetrically on the sun-exposed area of the body. It generally occurs due to more use of dermatological care products. The disease affects the quality of life of patient, due to frequent facial involvement. Some of the risk factor associated with the disease are pregnancy, sexual hormones, sun exposure, sue of cosmetics, photosensitizing drugs, steroids and inflammatory process of the skin. Patients generally feels lack of motivation to go out, anhedonia, low-self-esteem, dissatisfaction and feeling of shame. The University of Pittsburgh is in the process of developing TCA peel for the treatment of melisma. Allergan, Inc. is in the process of developing hydroquinone topical cream for the treatment of melisma. Some of the companies and universities having the pipeline of melisma include Allergan, Inc., Assiut University, University of Pittsburgh, and others.


The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.


About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Web: https://www.psmarketresearch.com

Wednesday, 14 February 2018

Pre-Eclampsia Therapeutics - Pipeline Review 2018, Clinical Trials & Results, Patent and Developments

Pre-eclampsia is a disorder of high blood pressure that causes decrease in blood supply to the growing foetus. The disease can be severe if left untreated, and can cause seizure or coma to the patient, a condition called as eclampsia. One of the complication associated with pre-eclampsia is HELLP syndrome which is characterized by low platelet count, hemolysis, and elevated liver enzymes. Some of the risk associated with pre-eclampsia that affects foetus are lack of nutrients and oxygen, preterm birth, and stillbirth. According to the Preeclampsia Foundation, each year, around 10,500 infants die in the U.S. A1M Pharma AB is in the process of developing A1M as a free radical scavenger, for the treatment of pre-eclampsia. VG Life Sciences Inc. is also in the process of developing VG 1177 as an immunomodulator, for the treatment of pre-eclampsia. Some of the companies and universities having the pipeline of pre-eclampsia include University of Pittsburgh, VG Life Sciences Inc., and others.


The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.


About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Web: https://www.psmarketresearch.com

Fungal Infections - Pipeline Review 2018

The fungal infection pipeline has more than 60 drugs. In pipeline analysis, drugs are analyzed based on route of administration and molecule type. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-clinical stage.
Phase III clinical trial known for the comparison of new treatments with the standard treatment in which the safety, efficacy and side effects of new intervention is compared with the already existing treatment. The Phase III clinical trial takes around 2-3 years to complete and the total number of participants vary from 100-1,000. After the completion of Phase III stage, the company filed New Drug Application to the regulatory authorities known as filed stage. There are 3 drugs for fungal infection in Phase III clinical trial. Terbinafine, also known as MOB-015, is a drug candidate of Moberg Pharma AB. The drug candidate is being developed for the treatment of onychomycosis. In fungal infection, no drugs have been registered for NDA filing.
VT-1161, a phase II drug candidate of Viamet Pharmaceuticals, Inc. for the treatment of onychomycosis (Fungal Infection) and recurrent vulvovaginal candidiasis. Phase II clinical trial is the second phase that answer safety, efficacy and dosing of the new intervention. There are total 14 drugs present in phase II trial of fungal infections. Phase II clinical trial take around 2 years to complete and between 100 – 120 patients participate in the Phase II trial.
PC945 is under development by Pulmocide Ltd. for the prevention and treatment for aspergillosis in cystic fibrosis, lung transplant and allergic bronchopulmonary aspergillosis. The drug candidate targets the cytochrome P450 C-14 alpha demethylase (CYP51) and inhibits its action. There are 8 drugs present in Phase I clinical stage. In Phase I clinical trial, safety of the new intervention is determined. The trial takes around 1-2 years to complete and the total number of volunteers participating in the trial vary between 15 – 30.
Pipeline analysis provides description about the key companies developing fungal infections drugs. Some of the key players actively involved in the research and development are Moberg Pharma AB, Viamet Pharmaceuticals, Inc., Pulmocide Ltd., Vyom Biosciences, NovaDigm Therapeutics Inc., Matinas BioPharma Holdings Inc., Sol-Gel Technologies Ltd. and Eisai Co. Ltd.

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)

Monday, 12 February 2018

Ocular Pain Treatment Market - Pipeline Analysis, Development and Growth, 2023

The global ocular pain treatment market is expected to witness considerable growth due to increasing awareness about the eye disorders, technological advancement in ocular therapeutic and diagnostic test, and increasing number of lifestyle related ocular diseases. In addition, increasing geriatric population and increasing disposable income are further supporting the growth of the global ocular pain market.


The pharmaceutical companies are actively involved in the research and development of drugs for ocular pain. Loteprednol etabonate, a Mucus-Penetrating Particle platform technology based Phase III clinical trial drug of Kala Pharmaceuticals, Inc., is nanotechnology based products for the treatment of ocular pain.

Ocular pain is defined as the inflammation of middle layer of eye known as uvea. It can develop in optic nerve, blood vessels, muscles or other tissues that surround the eye.  Many factors such as infection, allergy, surgery or trauma including blow to the eye, foreign body and chemical injury can lead to ocular inflammation. It is important to manage ocular pain, else it can affect other parts of eyes such as cornea, retina, sclera, conjunctiva and the vasculature. Ocular pain is caused by several conditions such as glaucoma, ocular herpes, shingles, optic neuritis, dry eye and refractive error.

Explore Report at: https://www.psmarketresearch.com/market-analysis/ocular-pain-treatment-market

Some of the key players operating in the global ocular pain market are ICON Bioscience Inc., Xigen S.A., Sylentis S.A., Bayer AG, Bristol Meyer Squibb Company, Merck and Co., Inc.,  Sun Pharmaceutical Industries Ltd., Reata Pharmaceuticals, Inc., Kala Pharmaceuticals, Inc. and Ocular Therapeutix, Inc.

Tuesday, 6 February 2018

Antibody Drug Conjugates Therapeutics Market - Pipeline Analysis, Size, Share and Growth, 2023

The global antibody drug conjugates therapeutics market is expected to witness significant growth due to current unmet medical need of some chronic diseases such as cancer and immunological diseases, increasing prevalence of such diseases, advancement in technologies and high demand for safe and effective medication. The regulatory bodies are supporting the ADCs market by providing designations and funding for speeding up the drug development process. In April 2015, ImmunoGen, Inc. drug candidate Mirvetuximab soravtansine got orphan drug designation by European Medicine Agency for the treatment of ovarian cancer.
The pipeline of ADCs is rich with more than 200 drugs. The pharmaceutical companies are actively involved in the research and development of drug for ADCs. Trastuzumab emtansineis, a Phase III clinical trial drug candidate of Genentech, Inc., utilizes Tumor-Activated Prodrug technology for the treatment of HER2-positive primary breast cancer. The drug is already marketed under trade name Kadcyla for the treatment of advanced human epidermal growth factor receptor 2 (HER2)-positive gastric cancer and early HER2-positive breast cancer.
ADCs are prepared by linking biologically active cytotoxic drugs to monoclonal antibodies. An ADC comprises of a monoclonal antibody, cytotoxic drug and a linker. ADCs have specific targeting ability of monoclonal antibody, and hence these are capable of distinguishing healthy and diseased cells. Moreover, the cancer-killing ability of cytotoxic drugs makes ADCs more effective against the tumor cells. These characteristics increase the specificity and maximize the efficacy of ADCs. The antibody component of ADCs recognizes the target antigen and binds with it. After binding with the antigen, the cytotoxic component is released inside the tumor cell, causing its death or degeneration. The significant potential of ADCs in cancer treatment has attracted many researchers and healthcare providers to develop new antibody therapeutics using ADC technology.
Some of the key players operating in the global market are ImmunoGen, Inc., Takeda Pharmaceutical Company Limited, Seattle Genetics, Inc., F. Hoffmann-La Roche AG, BioAtla LLC, Philogen S.p.A., Viventia Biotechnologies, Inc., Sutro Biopharma, Inc., Sorrento Therapeutics, Inc., and Immunobiochem Corporation.
About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Connect with us: LinkedIn | Twitter | Google + | Facebook

Natural Killer (NK) Cell Therapeutics Market - Pipeline Analysis, Market Size, Growth, 2023

The global natural killer cell therapeutics market is expected to witness considerable growth due to increasing awareness regarding immunotherapy, advancement in technologies, high demand for safe and effective medication, reduction of side effects, high prevalence of chronic diseases such as cancer and cardiovascular diseases, and increasing incidences of infectious diseases. The regulatory bodies are supporting the growth of the global market by providing funding, designations and grants for speeding up the drug development process. Some drug candidates, such as Mogamulizumab, Lorvotuzumab Mertansine, AFM 13, FPA144, and NKTT-120, got orphan drug designation and fast track designation for NK cell therapeutics.
The pipeline of NK cell therapeutics market is rich with more than 30 drugs. The pharmaceutical companies are actively involved in the research and development of drug for NK cells. Kyowa Hakko Kirin Co., Ltd. has Mogamulizumab drug in its Phase III clinical trial for NK cells therapeutics. Increasing use of combination therapy of NK cells is also a potential growth driver for the growth of the global market. Use of NK cells with Chimeric Antigen Receptor (CAR) T-Cell therapy helps to enhance the efficacy of the medication.
The pharmaceutical companies are collaborating with each other for research and development of NK cell therapeutics. For instance, in January 2016, Sanofi and Innate Pharma entered into research collaboration and licensing agreement to apply Innate Pharma’s new proprietary technology for the development of bispecific antibody formats engaging NK cells to kill tumor cells. The drug candidate has utilized the NK cells engagers bispecific antibodies technology to create novel molecular formats for engaging NK cells for tumor cells lysis. The bispecific antibodies specifically trigger NK cells instead of T cells, which may reduce the risk of the side-effects associated with T cell engagers.
However, certain factors such as side effects of NK cell medication, complex pathophysiology, and high treatment cost of NK cells are expected to hamper the growth of the global market during the forecast period.
Some of the key players operating in the global NK cells market are Chipscreen Biosciences, Ltd. Affimed N.V., Altor BioScience Corporation, Innate Pharma S.A., Takeda Pharmaceutical Company Limited, Sorrento Therapeutics Inc., NantKwest Inc., Bristol-Myers Squibb, and NKT Therapeutics, Inc.

Mammalian Target of Rapamycin Inhibitors Market - Pipeline Analysis, Market Size and Growth, 2023

The global mammalian target of rapamycin inhibitors market is witnessing considerable growth due to their application in several therapeutic areas such as cancer, renal dysfunction and eye disorders. The regulatory bodies are providing funding and designation to the drug candidates for advancement of their products. Moreover, the increasing awareness related to the effective use of mTOR inhibitors, in combination with chemotherapy and its implications in cancer therapy is also supporting the growth of global market. Different classification of mTOR inhibitors and their unique features is leading to their increased demand. Among the different generations of mTOR inhibitors, third generation mTOR inhibitors exploit the unique juxtaposition of two drug-binding pockets to create a bivalent interaction that allows inhibition of resistant mutants.
The involvement of antibiotics and proteins for drug development and technological advancements for mTOR inhibitors are expected to create ample growth opportunities for the global market. However, high cost of the marketed drugs and complexity in understanding the mechanism of action are the limitations associated with mTOR inhibitors, which are hampering the growth of the global market.
Geographically, North America was the largest market for mTOR inhibitors in 2015, owing to the large number of research and development activities, high healthcare expenditure, and high prevalence of chronic diseases such as cancer and cardiovascular diseases. The U.S. contributed largest revenue to the North American mTOR inhibitors market and it is expected to remain the largest market globally, during the forecast period. The supporting government regulations taken by the federal government is the key driving factor of the U.S. mTOR inhibitors market.
Europe is the second largest market for mTOR inhibitors. During the forecast period, the mTOR inhibitors market would witness highest growth in Asia-Pacific, attributed to increasing number of new entrants, improving healthcare infrastructure, increasing prevalence of chroic diseases and increasing healthcare expenditure.
The key players operating in the global market are Pfizer Inc., Novartis AG, AstraZeneca plc, Eli Lilly and Company, Ability Pharma, GlaxoSmithKline, MEI Pharma, Verastem, Inc., Phusis Therapeutics, Inc., and Co-D Therapeutics, Inc.

Radiation Dose Management Market - Industry Research Report Analysis, Size and Growth, 2023

According to the study, the global radiation dose management market is likely to develop at a CAGR of 46.0% during 2017-2023. RDM solutions and services are offered for various imaging modalities such as computed tomography (CT), nuclear medicine, fluoroscopy and interventional imaging, radiography and mammography, and others. RDM solutions and services are mostly utilized for monitoring radiation dose in CT. Globally, certain standards have been set up by the government to avoid high dose of radiation and have linked these doses to reimbursements, so that the radiologists give priority to the new guidelines. For instance, in 2014, National Equipment Manufacturers Association (NEMA) established certain guidelines under XR-29, for promoting low radiation dose standards. According to these guidelines, if the dose standards for CT are not followed it can bring down the reimbursement, as much as 15% for CT scanners that don’t meet the standards set forward by XR-29. Therefore, stringent regulatory requirements for diagnostic techniques supports the demand for RDM solutions and services.

Request for Report Sample at: https://www.psmarketresearch.com/market-analysis/radiation-dose-management-market/report-sample

As per the findings of the research, RDM solutions occupied the larger share of the global market in 2016, since these solutions enable the healthcare providers to track and evaluate the radiations emitting from different diagnostic procedures. The players in the industry provide services such as implementation and integration, support and maintenance, consulting and training and education. Among all the services, implementation and integration held the largest share of the market in 2016, since these services are associated with installation of solutions and integration with other systems in the healthcare settings.


Hospitals and super speciality clinics are the key end user of the RDM solutions and services and held largest share in 2016, mainly due to increasing number of installation of RDM solutions and growing number of diagnostic procedures in the treatment and management of diseases in the hospitals.


Globally, the key players in the market are introducing new solutions with advanced features in the market. For instance, in November 2016, Koninklijke Philips N.V. introduced DoseWise Portal 2.2, a next-generation radiation dose management software platform for healthcare providers to record, track and analyse radiation exposure to patients and clinicians.

GLOBAL RDM MARKET SEGMENTATION
By Product and Services
  • ·         Solutions

o    Integrated solutions
o    Standalone solutions
  • ·         Services

o    Implementation & integration services
o    Support & maintenance services
o    Consulting services
o    Training & education services

By Modality
  •         Computed tomography (CT)
  • ·         Nuclear medicine
  • ·         Fluoroscopy & interventional imaging
  • ·         Radiography & mammography
  • ·         Others

By End User
·         Hospitals
·         Super specialty clinics
·         Others
By Region
  • ·North America
    • U.S.
    • Canada
  • ·Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Rest of Europe
  •  Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • Rest of World (RoW)

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Web: https://www.psmarketresearch.com
Connect with us: LinkedIn | Twitter | Google + | Facebook